Jump to content
IndiaDivine.org

Guarded Response

Rate this topic


Guest guest

Recommended Posts

Guest guest

> " HSI - Jenny Thompson "

> <HSIResearch

 

> Guarded Response

> Thu, 22 Jul 2004 09:20:41 -0400

>

> Guarded Response

>

> Health Sciences Institute e-Alert

>

> Thursday July 22, 2004

>

>

**************************************************************

 

>

> Dear Reader,

>

> When my friend, Kelly, had a physical a few years

> ago, her doctor

> asked how things were going in her life. Things

> weren't good.

> Kelly's job was stressful, her marriage was on the

> rocks, and a

> family member had recently died. She admitted that

> she felt pretty

> blue most of the time. Her doctor asked her if she'd

> like to try

> Prozac.

>

> The idea shocked her. She'd never thought of herself

> as someone

> who would take an antidepressant drug. But she was

> also intrigued.

> The idea of a mental boost to help get through the

> day was

> appealing. So her doctor gave her a free sample pack

> of Prozac,

> and wrote a prescription to start off on a low dose.

>

>

> Later Kelly told me that on the drive home from her

> doctor's office

> her spirits were better than they'd been for months.

> She felt

> empowered and hopeful – like a dark cloud had

> lifted. In short, she

> didn't feel the least bit depressed. And at this

> point she hadn't

> taken her first dose of the Prozac.

>

> What Kelly was experiencing was similar to a placebo

> effect. What

> she needed most in her life was not a drug, but the

> feeling that

> someone – or something – was in her corner, offering

> a helping

> hand. And it's people like Kelly who have been

> messing up the

> results of clinical trials for antidepressant drugs.

> In some cases the

> positive results in these trials were stronger among

> placebo

> subjects than those taking the drugs.

>

> Well... we can't have that! So now drug companies

> are devising

> ways to weed out study subjects like Kelly –

> subjects known as

> " placebo responders. "

>

>

----------

>

> Cordially uninvited

>

----------

>

>

> Now, you know I'm not one to put a lot of stock in

> headlines, but

> the recent headline of a Wall Street Journal (WSJ)

> article summed

> up the situation in a nutshell: " Drug Makers Seek to

> Bar 'Placebo

> Responders' From Trials "

>

> The WSJ article reports that Eli Lilly (maker of

> Prozac) and Pfizer

> (maker of Zoloft) are funding research on brain

> imaging at the

> University of California, Los Angeles. This research

> is designed to

> identify disruptions in sleep and thought processes

> experienced by

> depressed subjects. But some depressed patients

> don't experience

> these disruptions, and it's these patients who are

> believed to be

> placebo responders.

>

> According to WSJ, Pfizer researchers have also

> conducted studies

> indicating that placebo responders may be identified

> through DNA

> testing.

>

> It's an efficient plan: Spot the troublemakers, keep

> them out of the

> trials, and the outcome will probably be much more

> in line with

> desired results. The key word here is " desired. "

> Accurate results

> are secondary to desired results when an FDA

> approval of a cash

> cow pharmaceutical is in the balance.

>

> Drug companies claim that the techniques designed to

> exclude

> placebo responders would only be used for early

> trials – not for

> FDA approval trials.

>

> Naaa! They wouldn't do that! They have too much

> integrity!

>

> But think about it: That very claim indicates an

> awareness that – at

> worst – there may be something unethical about this

> practice,

> while – at best – it corrupts the basic design of

> clinical studies.

>

>

---------

>

> Going off the gold standard

>

---------

>

>

> Kay Dickersin, a professor at Brown University and

> the director

> for the Center for Clinical Trials and

> Evidence-Based Healthcare at

> Brown, told WSJ that placebo responder screening

> encourages bias

> with a " subtle manipulation " of trial results. I

> think Professor

> Dickersin is being charitable. This manipulation is

> not so subtle at

> all.

>

> The gold standard for clinical trials calls for

> three elements:

>

> * Placebo-control (one group receives an active

> agent while

> another receives a placebo)

> * Double-blinding (neither the subjects nor those

> who administer

> the study are aware of which subjects receive

> placebo)

> * Randomization (once the group of study subjects

> are in place,

> they are randomly assigned either placebo or

> active agent).

>

> So when you're studying the effects of an

> antidepressant on mildly

> depressed subjects, and you remove any subjects who

> qualify as

> mildly depressed but who will probably respond to

> placebo, then

> you're compromising the randomization. The results

> of your trial

> will indicate how a drug works only on those

> subjects who are not

> placebo responders. The implication: The drug won't

> be tested on

> placebo responders, but it doesn't matter because,

> you know,

> ANYthing works on them!

>

>

---------

>

> Included out

>

---------

>

>

> Research that involves brain imaging and genetics

> doesn't come at

> bargain prices. So the fact that two huge drug

> companies are

> willing to underwrite such expensive research

> reveals to what

> lengths companies will go to tip the balance of

> clinical trials in

> their favor. Now, with new antidepressants in

> development for

> both Pfizer and Lilly, just think how successful

> upcoming trials

> might be if those pesky placebo responders simply

> get included

> out.

>

> P.S.: Kelly did try the Prozac, but stopped using it

> after one month.

> She said the drug made her feel woozy. So she

> started taking St.

> John's Wort and that was enough to see her through a

> mild

> depression during a tough time.

>

>

**************************************************************

 

> ...and another thing

>

> " A rose hip by any other name... "

>

> Vitamin C terminology is the subject of a recent

> e-mail, signed by

> HSI members Ginger and Larry. G & L write:

>

> " It seems to me that someone is missing the fact

> that vitamin C is

> NOT the exact same item as ascorbic acid, ever

> though it is often

> measured that way. The entire complex of C includes

> elements

> that Jonathan V. Wright and others have written

> about often and I

> feel, as a chiropractor learning as much as I can

> from the big guys

> about nutrition, that there is something there that

> should be taken

> into account. Comments? "

>

> It's true that the terms " vitamin C " and " ascorbic

> acid " are often

> used interchangeably, but shouldn't be. In the

> e-Alert " Attack of

> the Vapors " (1/6/04), here's what HSI Panelist Allan

> Spreen,

> M.D., had to say about ascorbic acid:

>

> " This is the standard form of vitamin C. Calcium

> ascorbate is one

> of the salt forms of the nutrient (as opposed to the

> acid form). It is

> usually synthetic, as are other forms, such as

> sodium ascorbate,

> magnesium ascorbate, etc. It tends to be bitter,

> while ascorbic acid

> is sour. "

>

> And on the natural vs. synthetic forms of vitamin C,

> Dr. Spreen

> again: " The synthetic vitamin C molecule is

> chemically identical to

> natural forms. The difference arises in other

> nutrients that

> accompany the C, such as bioflavonoids, which make

> the C more

> effective. That's not to say that I don't prefer

> natural; it's just that

> it's very hard to come by, and extremely expensive. "

>

>

> " Attack of the Vapors " provides a compact but

> thorough look at

> vitamin C, courtesy of Dr. Spreen, and can be easily

> found by

> going to our web site (www.hsibaltimore.com), and

> using the

> " Search the e-Alert archives " feature to find

> e-Alerts on this and

> many other health and nutrition topics. (In this

> case, just use the

> keywords " Spreen " and " ascorbic " to find the vitamin

> C e-Alert.)

>

> To Your Good Health,

>

> Jenny Thompson

> Health Sciences Institute

>

>

> Sources:

> " Drug Makers Seek to Bar 'Placebo Responders' From

> Trials "

> Leila Abboud, The Wall Street Journal, 6/18/04

>

Link to comment
Share on other sites

Join the conversation

You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

Loading...
×
×
  • Create New...